NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo. Site preparation and staff training are scheduled for early April 2026, with the study already approved by the DRC regulatory agency. The trial will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA.
The importance of this development lies in addressing a significant global health threat. MPox, formerly known as monkeypox, has caused outbreaks in multiple countries, with Clade I being particularly severe. The Democratic Republic of Congo has experienced ongoing MPox transmission, making it a critical location for clinical research. A successful treatment could reduce mortality rates, alleviate healthcare burdens in affected regions, and provide a tool for controlling future outbreaks. The company's progress toward Phase II trials represents a meaningful advancement in antiviral development for a disease that currently lacks specific approved treatments.
NV-387 is NanoViricides' lead drug candidate, described as a broad-spectrum antiviral drug that the company plans to develop for multiple viral infections including RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's platform technology is based on intellectual property from TheraCour Pharma, Inc., with which NanoViricides has a Memorandum of Understanding for developing drugs based on these technologies for all antiviral infections. According to the company's website at https://www.nanoviricides.com, NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy.
The company's regulatory strategy includes seeking Orphan Drug Designation from the U.S. FDA, which could provide development incentives and market exclusivity if approved. This designation is particularly relevant for diseases like MPox that affect smaller patient populations. The trial in the Democratic Republic of Congo represents an important step in gathering clinical data that could support regulatory submissions in multiple jurisdictions.
For the pharmaceutical industry, this development highlights continued investment in antiviral research beyond the COVID-19 pandemic. The company's broad approach to developing treatments for multiple viral diseases, including those listed in their perpetual license agreement such as Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C, Rabies, Herpes Simplex Virus, and Ebola/Marburg viruses, demonstrates the potential versatility of their platform technology. However, as the company notes in its risk disclosures, the path to drug development is lengthy and requires substantial capital, with no assurance that pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The Phase II trial initiation represents a critical milestone for NanoViricides as it advances its lead candidate through clinical development while addressing an important public health need in a region significantly affected by MPox outbreaks.
